Improving the ability of the kidney to tolerate ischemic injury has important implications. We investigated the effect of recombinant human erythropoietin (rHuEPO) treatment on subsequent ischemia/reperfusion (I/R) injury and evaluated the role of heat shock protein (HSP) 70 in rHuEPO-induced renal protection. rHuEPO (3000 U/kg) was administered 24 h before I/R injury, and rats were killed at 24, 48, and 72 h after I/R injury. Pretreatment of rHuEPO resulted in the following: i) decreased serum creatinine level; ii) decreased tubular cell apoptosis and necrosis, measured by DNA fragmentation analysis and TUNEL staining and histomorphological criteria; iii) decreased tubular cell proliferation as determined by proliferating cell nuclear antigen expression; iv) increased bcl-2 protein and decreased caspase 3 activity; and v) decreased JNK expression. rHuEPO treatment increased HSP70 expression in a dose-dependent manner in normal rat kidneys, and inhibition of HSP70 expression by quercetin eliminated the renoprotective effect of rHuEPO in ischemic kidneys. Our study demonstrates that rHuEPO has a protective effect on subsequent I/R injury and that this effect is associated with induction of HSP70. Our study provides a new avenue for therapy to prevent renal damage after I/R injury.
I
Erythropoietin (EPO) was first characterized as a hematopoietic growth factor and has been use clinically by millions of patients over the past decade for the treatment of anemia (7) . In addition to its hematopoietic effect, EPO plays an important role during acute renal failure repair process by rapidly correcting anemia (8) and enhancing renal tubular regeneration (9) . Moreover, several independent research groups have reported that EPO protects cultured neurons against glutamate toxicity (10) and reduces ischemic neuronal damage and neurobiological dysfunction in rodent models of stroke (11) (12) (13) , suggesting a preventive effect of EPO against ischemc or toxic injuries.
The HSP70 family is capable of protecting cells, tissues, organs, and animals from a subsequent, normally lethal heating as well as from numerous disease states. HSP70 functions as a molecular chaperon and reduces stress-induced denaturation and aggregation of intracellular proteins (14) . In addition, HSP70 exerts antiapoptotic effects by interfering with the stress-induced apoptotic program (15) . Indeed, the role of HSP70 in ameliorating I/R injury has been documented in transfected cells or transgenic murine tissues overexpressing HSP70 protein (16, 17) . In general, HSP70 is induced in response to a variety of stresses (18, 19) , but nontoxic HSP70 inducers are also reported (20) (21) (22) (23) . Therefore, it would be of great therapeutic benefit to discover compounds that are clinically safe yet able to induce HSP70 in kidney.
Until now, it has not been tested whether rHuEPO has a renoprotective effect in ischemic kidney. Moreover, it has not been assessed whether rHuEPO induces HSP70 expression in kidney. An in vivo study was therefore performed to evaluate whether rHuEPO can be used effectively as an inducer of ischemic tolerance. First, we asked whether a single i.v. injection of rHuEPO would be sufficient to prevent subsequent I/R injury. Second, we evaluated whether renoprotective effects of rHuEPO are related to the induction of HSP70 by rHuEPO. The results of our study provide the evidence that rHuEPO is an effective inducer of ischemic tolerance, and renoprotection of rHuEPO is closely associated with induction of HSP70 by rHuEPO.
MATERIALS AND METHODS

Antibodies
Phospho-p44/42 and total-p44/42MAP kinase (ERK1 and ERK2) as well as phospho-SAPK/JNK and total-SAPK/JNK MAP kinases were purchased from Cell Signaling Technology (Beverly, MA). HSP70 protein was purchased from Sigma (St. Louis, MO), and PCNA protein (PC10) was purchased from Dako (Copenhagen, Denmark)
Animals and drugs
Adult male Sprague-Dawley rats, weighing ~250-300 g, were housed in individual cages in a temperature-and light-controlled environment under a 12-h light, 12-h dark cycle, and food and water were available ad libitum. The rHuEPO was provided by CJ Corporation (Seoul, Korea) and was injected i.v. via penile vein. All injections were diluted with sterile saline and adjusted to a final concentration of 3000 U of rHuEPO in 1.0 cc, with similar volumes of sterile saline given to control rats.
Experimental protocol
The experimental protocol was approved by the animal ethics review committees of our institutions. Two experimental protocols were used: Protocol 1 was designed to evaluate the effect of pretreatment of rHuEPO on subsequent I/R injury, and protocol 2 was designed to evaluate the role of HSP70 in rHuEPO-induced renal protection in rat kidney with I/R injury.
In protocol 1, rHuEPO (3000 U/kg) was administered 24 h before I/R injury, which was induced by clamping both renal arteries for 45 min. Rats were killed at 24, 48, and 72 h after I/R injury. Sham operations were performed in a similar manner, except that the renal vessels were not clamped. One hundred and twenty-eight rats were used. Each group comprised 32 rats, and 8 rats were used at each time. The dose (3000 U/kg) was chosen based on a previous report that this dose is effective in recovery from postischemic renal tubular necrosis (8) . Serum creatinine levels and hematocrit levels were evaluated at 24, 48, and 72 h after I/R injury, and other parameters were evaluated at 24 h after I/R injury.
In protocol 2, the role of HSP70 in rHuEPO-induced renal protection in rat kidney with I/R injury was investigated. First, time-and dose-dependent HSP70 expression was studied. Rats were treated with rHuEPO (3000 U/kg) and killed at 0, 6, 12, 24, 48, and 72 h after treatment. Forty-eight rats were used, eight at each time point. After determining the time course of HSP70 expression, rats were treated with different doses of rHuEPO (0, 500, 1000, 3000 U/kg) to evaluate the dose-dependent HSP70 expression. Thirty-two rats were used, eight at each dose. To evaluate the role of HSP70 in rHuEPO-induced renoprotection, quercetin (100 mg/kg), a HSP70 inhibitor, was administered i.p. 2 h before rHuEPO treatment in sham-operated rats or rats with ischemic injury (24) . The rats were then killed 24 h after I/R injury. Seventy-two rats were used to evaluate the influence of quercetin on HSP70 expression (32 rats, 8 rats in each group) and renoprotective effect of rHuEPO (40 rats, 8 rats in each group).
Functional studies
Serum creatinine was measured by a Cobas autoanalyzer (Roche Diagnostics, Div. Hoffman-La Roche, Nutley, NJ). Hematocrit (Hct) was used as an indicator of anemia, using an Hct tube and centrifugation at 10,000 r.p.m. for 5 min.
Preservation of kidneys
The kidneys were perfused briefly through the abdominal aorta with phosphate-buffered saline (PBS) to rinse out the blood and subsequently preserved by in vivo perfusion with a periodatelysine-paraformaldehyde (PLP) solution for 4 min. They were cut into sagittal slices and then were immersed in PLP overnight at 4°C. After being rinsed in PBS, some tissues were dehydrated in a graded series of ethanol and embedded in wax (polyethylene glyco 400 dissterate; Polysciences, Warrington, PA).
Histologic examination
Renal tissues were embedded in wax. Four-micrometer sections were stained with periodic acidSchiff (PAS) reagents. Tubular injury was scored semiquantitatively using a scoring system ranging from 0 to 4 by a blinded observer who examined at least 40 fields (200× magnification) (25) . Tubular injury was defined as a tubular dilatation, sloughing of tubular epithelial cells, or naked tubular basement membrane. Only tubules in the outer strip of the outer medulla (most sensitive zone for ischemic injury) were included, and scoring was calculated using digital image analyzer (TDI Scope Eye version 3.0 for Windows; Olympus, Japan). The scoring system was as follows: 0, no tubular injury; 1, <20% of tubules injured; 2, 21-50% tubules injured; 3, >50% damage of tubule cells; 4, total destruction of all epithelial cells.
TUNEL assay
The ApopTag in situ apoptosis detection kit (Oncor, Gaithersburg, MD) was used. The sections were dewaxed and treated with proteinase K, then incubated with equilibration buffer for 10 min, followed by incubation with working-strength TdT enzyme solution at 37°C for 2 h. The reaction was terminated by incubation in working-strength stop/wash buffer for 30 min at 37°C. Sections were then incubated with antidigoxigenin peroxidase and then incubated with diaminobenzidine and 0.01% H 2 O 2 for 5 min at room temperature. The sections were counterstained with hematoxylin and examined by light microscopy. The number of TUNEL-positive cells was counted in 20 unoverlapped fields in each section under 200× magnification (26) .
DNA fragmentation analysis
Genomic DNA was extracted from outer medulla using Easy DNA extraction kit (Invitrogen, San Diego, CA). Ten micrograms of DNA were electrophoresed on a 3% agarose gel. Fragmented DNA was visualized by ethidium bromide under an UV light source.
Enzyme activity assay
Activities of caspase-3 were assayed in whole kidney tissue as described previously (19) . In brief, the kidney tissue samples were homogenized in lysis buffer containing 10 mM HEPES/KOH (pH7.2), 2 mM EDTA, 0.1% CHAPS, 5 mM dithiothreitol, 1 mM phenylmethylsulphonylfluoride (PMSF), 10 µg/ml aprotinin, and 20 µg /ml leupeptin. The lysate was centrifuged at 25,000g for 10 min at 4°C, and supernatants were incubated for 1 h at 37°C with 10 nmol of fluorogenic substrates (Ac-DEVD-AMC for caspase-3 substrate). Substrate cleavage was measured with a spectrofluorometer (Fluoroskan II) and was corrected as protein content in lysate. Controls (including buffer, substrate, and extracts alone) were assayed in parallel and subtracted from experimental values.
Immunohistochemistry for PCNA
Sections were dewaxed, rehydrated, and incubated with 3% H 2 O 2 . After treatment with blocking serum, the sections were incubated with the primary antibody to PCNA. Sections incubated without primary antibody served as controls. Sections were rinsed in PBS, incubated with biotinylated secondary antibody, and subsequently with the Vectastatin ABC reagent for 60 min. After being rinsed with PBS, the sections were incubated with the peroxidase substrate solution. After immunostaining, sections were counterstained with hematoxylin.
Immunoperoxidase preembedding method for HSP70 (27)
Vibratome sections (50 µm thick) were washed with 50 mM NH 4 Cl in PBS three times for 15 min. Before incubation with the primary antibody, all tissue sections were incubated for 3 h with PBS containing 1% bovine serum albumin, 0.05% saponin, and 0.2% gelatin (solution A). The tissue sections were then incubated overnight at 4°C in rabbit antisera against HSP70 in PBS containing 1% bovine serum albumin (solution B). After several washes with solution A, the tissue sections were incubated for 2 h in peroxidase-conjugated donkey anti-rabbit IgG Fab fragment (Jackson ImmunoResearch Laboratories, West Grove, PA) diluted 1:100 in solution B. The tissues were then rinsed, first in solution A and subsequently in 0.05 M Tris buffer, pH 7.6. For the detection of horseradish peroxidase, the sections were incubated in 0.1% 3,3′-diaminobenzidine in 0.05 M Tris buffer for 5 min, after which H 2 O 2 was added to a final concentration of 0.01% and the incubation was continued for 10 min. After being washed with 0.05 M Tris buffer three times, the sections were dehydrated in a graded series of ethanol and embedded in poly/Bed 812 resin (Polysciences). After several washes with PBS, the tissue sections were incubated for 2 h in horseradish peroxidase-conjugated donkey anti-rabbit IgG Fab fragment (Jackson ImmunoResearch Laboratories) diluted 1:100 in solution B. The tissues were then rinsed in PBS, pH 7.4, and, for the detection of horseradish peroxidase, the sections were incubated in vector SG (blue; Vector Laboratories, Burlingame, CA) in PBS for 5 min, followed by H 2 O 2 incubation for 10 min. After being washed with PBS three times, the sections were dehydrated in a graded series of ethanol and embedded in poly/Bed 812 resin.
For light microscopy, 1-µm sections were cut, the plastic resin was removed by etching with a saturated solution of sodium hydroxide in alcohol, and the sections were stained with hematoxylin. The sections (50 and 1 µm) were examined and photographed with an Olympus photomicroscope equipped with differential-interference contrast optics.
For electron microscopic observation, Vibratome sections were postfixed with 1% glutaraldehyde and 1% osmium tetroxide in 0.1 M phosphate buffer, pH 7.4, before being dehydrated and embedded in poly/Bed 812 resin. Ultrathin sections were stained with uranyl acetate and lead citrate and photographed with a transmission electron microscope (JEOL 1200EX, Tokyo, Japan).
Immunoblot
Tissues were homogenized in RIPA (10 Homogenates were centrifuged at 16,000g for 15 min at 4°C, and protein concentrations were determined on supernatants using the Bradford method protein microassay (Bio-Rad, Hercules, CA). Homogenates were boiled at 94°C for 5 min in Laemmli sample buffer. Proteins were separated by SDS-PAGE in 15% polyacrylamide gels and were electroblotted onto Bio-Blot nitrocellulose (Costar, Cambridge, MA). Nonspecific binding was blocked by incubating the blots for 1 h in 5% (wt/vol) nonfat milk. Blotted proteins (PCNA, HSP70, ERK, and JNK protein) were incubated overnight with each primary antibody, and then followed by washes with Tris-buffered saline (TBS-T) containing 0.005% Tween 20 (TBS-T).
The blots were then incubated with peroxidase-conjugated antibody and were detected using enhanced chemiluminescence kit (Amersham Life Sciences, UK). Densitometric analysis was performed using Gelexpert software (Nucleotech, San Carlos, CA). Optical densities (mean ±SE) were obtained in all animals after three determinations for each band; expression of each protein was described throughout as the proportional increase or decrease relative to the levels observed in the sham-operated rat kidney.
Statistical analysis
Data reported are mean ±SE. Multiple comparisons among groups were done by one-way ANOVA with post hoc Bonferroni test correction (SPSS 9.0 Microsoft). The level of statistical significance was P<0.05.
RESULTS
Effect of rHuEPO pretreatment on hematocrits and renal function
Hematocrit levels in rHuEPO-pretreated sham-operated or ischemic rat were not significantly different from those without rHuEPO treatment 24, 48, and 72 h after I/R injury (Fig. 1A) , indicating that there was no hematopoietic effect after a single injection of rHuEPO (3000 U/kg). Renal function measured by serum creatinine levels 24 h after I/R injury was severely increased in the rat with I/R injury compared with sham-operated rats (1.6±0.3 vs. 0.6±0.0 mg/dl, P<0.05). However, rHuEPO pretreatment significantly decreased serum creatinine levels compared with I/R group (1.2±0.2 vs. 1.6±0.3 mg/dl, P<0.05) (Fig. 1B) Effect of rHuEPO treatment on proliferative activity assessed by immunoblotting and immunohistochemistry of PCNA To investigate whether rHuEPO treatment affects cell proliferation, we evaluated PCNA expression in kidneys from the different groups of rats. Immunoblotting to detect the PCNA protein demonstrated a single band of 36 kD (Fig. 2A) , and densitometric analysis revealed that rHuEPO treatment significantly increased PCNA expression in sham-operated rat kidneys compared with those without rHuEPO treatment (136±11% vs. 102±6%, P<0.05). In rat kidneys with I/R injury, PCNA expression was significantly increased, but pretreatment of rHuEPO decreased PCNA expression (283± % vs. 217±29%, P<0.05) (Fig. 2B) . Immunohistochemistry of PCNA revealed that pretreatment of rHuEPO decreased the number of PCNA-positive cells, which were more prevalent in rat kidneys with I/R injury (Fig. 2C) .
Effect of rHuEPO pretreatment on medullary congestion and tubular necrosis induced by I/R injury
Gross examination of kidneys 24 h after the I/R injury revealed significant outer medullary congestion, whereas there was dramatic decrease in medullary congestion in rHuEPO-pretreated ischemic kidneys (Fig. 3A) . Histologic examination of PAS-stained kidney sections indicated much less necrosis of proximal tubule cells and less obstruction and red cell trapping in the outer medulla of rHuEPO-treated animals compared with kidneys of rats with I/R injury (Fig. 3B) . Quantitative analysis of tubular necrosis showed a dramatically decreased necrosis score in rHuEPO-pretreated rat kidneys compared with rats with I/R injury (1.3±0.6 vs. 2.6±0.6, P<0.05) (Fig. 3C) 
Effect of rHuEPO pretreatment on apoptotic cell death induced by I/R injury
Apoptosis was evaluated by DNA fragmentation analysis and TUNEL immunostaining to localize DNA fragmentation. As shown in Figure 4 , typical DNA laddering pattern and increased TUNEL-positive cells were observed in I/R rat kidneys. With rHuEPO pretreatment, DNA laddering was undetectable and TUNEL-positive cells were significantly decreased compared with the I/R group. rHuEPO pretreatment of sham-operated rats caused a 2.7-fold increase in bcl-2 protein compared with rats without rHuEPO pretreatment. In rat kidneys with I/R injury, bcl-2 protein decreased significantly compared with sham-operated rat kidneys (49±21% vs. 104±10%, P<0.05). However, rHuEPO pretreatment before I/R injury caused a 5.2-fold increase of bcl-2 protein expression compared with those without rHuEPO treatment (Fig. 5A ). Caspase-3 proteolytic activity was increased in the I/R group compared with the sham group (19.3±2.8 vs. 14.1±0.3 ng/µg protein, P<0.05). After pretreatment of rHuEPO, caspase-3 activity decreased significantly compared with that in the I/R group (13.3±0.4 vs. 19.3±2.8 ng/µg protein, P<0.05; Fig. 5B ).
Effect of rHuEPO pretreatment on MAPK activation after I/R injury
To determine the mechanisms that determine both survival promotion and control of cell death process after rHuEPO pretreatment, we examined the activity of ERKs and JNKs as a part of "survival" and "death" pathways. As shown in Figure 6 , in rat kidneys with I/R injury, ERK or JNK expressions increased significantly compared with sham-operated rat kidneys (EFK: 3.2-fold; JNK: 6.7-fold). rHuEPO pretreatment did not inhibit activation of ERK in ischemic rat kidneys 24 h after I/R injury, whereas a significant reduction in JNK expression was observed, which indicates that rHuEPO treatment regulates the balance of ERK/JNK activities by inhibiting JNK activity.
HSP70 expression in rHuEPO-treated rat kidneys
To determine whether rHuEPO induces HSP70, we examined time-and dose-dependent HSP70 expression in rHuEPO-treated rat kidneys. As shown in Figure 7A , the rHuEPO treatment (3000 U/kg) increased HSP70 at 6 h. Maximal increase was seen at 24 h, and thereafter expression decreased. Figure 7B shows the dose-dependent response in HSP70 expression. HSP70 expression induced by rHuEPO increased at 500 U/kg (cortex, 177%; medulla, 155%) and gradually increased up to 3000 U/kg (cortex, 401%; medulla, 761%) compared with shamoperated rat kidneys. This indicates dose-dependent HSP70 expression in response to rHuEPO ( Figure 7C and 7D) .
To determine the localization of HSP70 in rHuEPO-treated rat kidneys, immunohistochemical and electron microscopic examination was performed. HSP70 immunoreactivity was faintly expressed on renal tubular cells in the outer medulla of sham-operated rat kidney (Fig. 8A and  8C ), and its immunoreactivity was strikingly increased by rHuEPO treatment (Fig. 8B and 8D ).
Electron microscopic examination revealed that HSP70 immunoreactivity was newly expressed in the collecting cell in the EPO treatment group (Fig. 8E-H) .
Effect of quercetin on HSP70 expression and rHuEPO-induced renal protection
To define the role of HSP70 in rHuEPO-induced renal protection, sham and I/R groups were pretreated with quercetins. As shown Figure 9A , quercetin completely inhibited the HSP70 expression induced by rHuEPO treatment. In rat kidneys with I/R injury, quercetin pretreatment alone did not affect renal function and histopathology, but pretreatment of quercetin before rHuEPO treatment eliminated the renoprotective effect of rHuEPO (Fig. 9B-D) .
DISCUSSION
In the present study, we provide strong evidence that rHuEPO has a preventive effect against I/R injury in rat kidneys. rHuEPO-pretreated kidneys showed markedly reduced outer medullary congestion with functional protection following I/R injury. Furthermore, histological examination revealed less necrosis of proximal tubule and less obstruction in the outer medulla in rHuEPO-pretreated rat kidneys than in ischemic rat kidneys. Interestingly, rHuEPO pretreatment did not affect hematocrit levels and even decreased renal tubular cell proliferation in ischemic rat, suggesting that the renoprotective effect of rHuEPO is independent of its growthpromoting effects. Based on these findings, we propose that EPO pretreatment effectively induces ischemic tolerance against subsequent I/R injury in kidneys, as was well defined in EPOpretreated neuronal cells (28) .
Apoptosis and necrosis have been proposed as the mechanisms that produce cellular demise in ischemic rat kidneys (29) , and either one may be the target of actions of EPO. In the present study, I/R injury increased tubular cell necrosis with destruction of structure, typical DNA laddering pattern, and increased TUNEL-positive cells. At the molecular basis, bcl-2 protein expression decreased and caspase-3 activity increased at 24 h after I/R injury. However, rHuEPO treatment before I/R injury decreased apoptotic cell death and was accompanied by decreased activities of caspase-3 and increased bcl-2 protein expression. Interestingly, rHuEPO treatment to sham-operated rats also increased bcl-2 protein expression compared with control kidneys. The results demonstrate that apoptosis, as well as necrosis, is associated with cell death in rat kidney with I/R injury (30, 31) and that rHuEPO exerts its antiapoptotic effect by inducing bcl-2 protein in kidneys, as was previously observed in EPO-pretreated microglial cells (32) .
Studies in several cellular systems have indicated that the activation of ERKs during JNK activation can block the deleterious nature of the JNK response and lead to cellular survival (33) (34) (35) . Our demonstration of increases in JNK and ERK activation with ischemia is consistent with previous published results from our laboratory (36) and others (37) . In rat kidneys with I/R injury, cell survival depends on ERK activation (38) , and inhibition of JNK during ischemia ameliorates renal failure (39) . Therefore, inducing ischemic tolerance might change MAPK expression in ways that promote cell survival. A mouse model of ischemic preconditioning showed reduced JNK activation but had no effect on postischemic activation of ERK (40) . Our study produced similar results. Pretreatment of rHuEPO did not affect up-regulated ERK expression but decreased JNK expression in ischemic rat kidneys. These data suggest that differential regulation of MAPK by rHuEPO pretreatment favors protection against I/R injury.
The results of our study clearly demonstrate that renoprotection by rHuEPO is closely associated with HSP70. In this study, rHuEPO-induced HSP70 was dose-dependent (500→1000→3000 U/kg) and time-dependent (6→12→24 h), and rHuEPO treatment strikingly increased immunoreactivity of HSP70 in the inner stripe of the outer medulla (41) , where there is an area vulnerable to I/R injury (42) . Furthermore, inhibition of HSP70 expression by quercetin treatment eliminated rHuEPO-induced renoprotective effect in ischemic rat kidney. These findings suggest that rHuEPO treatment leads to new production of HSP70 in renal tubular cells, and induction of HSP70 by rHuEPO is causally related to this observed protective function.
Through our study, we demonstrated that rHuEPO produces HSP70, but it is still unknown how rHuEPO induces HSP70. In neuronal cells, initiation of the cascades that modulate protection by EPO and its receptor may begin with the activation of the Janus tyrosine kinase (JAK) 2 protein (43). Subsequent downstream mechanisms appear to lead to the activation of multiple signal transduction pathways that include transcription factor STAT5 (signal transducers and activators of transcription), bcl-2, protein kinase B, cysteine proteases, MAPK, protein-tyrosine phosphatases, and nuclear factor-κB (32, (44) (45) (46) . HSP70s are among subsets of stress-responsive proteins regulated by activation of JAK/STAT pathway (47) . Therefore, we speculate that activated JAK/STAT pathway by rHuEPO may help renal tubular cells adapt to I/R injury by upregulating HSP70.
In general, HSP70 inhibits a signal transduction pathway leading to apoptosis by preventing stress-induced activation of JNK and p38 activation (48, 49) . In addition, HSP72 strongly reduces the activation of stress-induced kinases in response to tumor necrosis factor-α and interleukin-1 (50) and decreases apoptotic cell death and proapoptotic genes that appear following I/R injury (51) . Therefore, we propose that induction of HSP70 by rHuEPO inhibits apoptotic cell death in rat kidneys with I/R injury by inhibiting MAPK activity, as observed in this study.
The ability of rHuEPO to induce ischemic tolerance suggests that there are advantages in its application in kidney transplantation. First, a rHuEPO is a safe drug in clinical practice. Second, the induction time of ischemic tolerance is relatively rapid (24 h) after a single injection of rHuEPO. Third, there is no additional or special equipment required for the induction of tolerance. Fourth, donor treatment of rHuEPO may be effective in preventing anemia after operation (52) . Clinical studies will be necessary to evaluate the therapeutic properties of rHuEPO in preventing I/R injury not only in kidneys but also in transplantation of other solid organs. 1 . Effect of rHuEPO on hematocrits and renal function in rats with sham-operation and ischemiareperfusion injury. A) Hematocrits levels. Note no significant difference in hematocrit levels between study groups, suggesting rHuEPO has no hematopoietic effect. B) Serum creatinine levels. In rats with I/R injury, serum creatinine levels increased significantly compared with sham-operated rats, but rHuEPO pretreatment decreased serum creatinine levels compared with rats with I/R injury alone.
# P < 0.05 vs. sham group; ## P < 0.05 vs. I/R group. S: sham-operated rats treated with saline; E+S: sham-operated rats treated with rHuEPO; I/R: rats subjected to ischemia followed by reperfusion; E+I/R: rats treated with rHuEPO before ischemia followed by reperfusion. Immunoblot of bcl-2. Note the significant increase in bcl-2 protein in sham-operated rat kidney as well as ischemic rat kidneys with rHuEPO pretreatment compared with rats without rHuEPO treatment. # P < 0.05 vs. sham group; ## P < 0.05 vs. I/R group. S: sham-operated rats treated with saline; E+S: sham-operated rats treated with rHuEPO; I/R: rats subjected to ischemia followed by reperfusion; E+IR: rats treated with rHuEPO before ischemia followed by reperfusion. B) Caspase-3 activity. In rat kidneys with I/R injury, caspase-3 activity increased significantly compared with sham or rHuEPO-pretreated sham rat kidneys. With rHuEPO pretreatment, caspase 3 activity decreased significantly. Kidneys from sham-operated rats treated with saline (S) or rHuEPO (E) and ischemic kidneys from rats treated with saline (I/R) or rHuEPO 24 h before ischemia removed after 24 h after reperfusion. ERK and JNK activation were revealed in whole tissue lysates by Western blot anlaysis, using anti-phospho-ERK (p-ERK) and phospho-JNK (p-JNK) antibodies. The same membranes were stripped and reblotted with total-ERK (t-ERK) and total-JNK (t-JNK). The blots are representative of the results obtained from six animals. A) ERK expression. In rat kidneys with I/R injury, there was an almost threefold increase in ERK expression compared with the sham group. However, rHuEPO pretreatment did not affect ERK expression.
# P < 0.05 vs. sham group; ## P < 0.05 vs. I/R group. B) JNK expression. In rat kidneys with I/R injury, JNK expression increased significantly but decreased with pretreatment of rHuEPO. Data shown are mean ±SE for four independent experiments performed in triplicate.
# P < 0.05 vs. sham group; ## P < 0.05 vs. I/R group. The influence of quercetin on rHuEPO-induced HSP70 expression. Note the significant decrease in HSP70 protein expression after pretreatment of quercetin.
# P < 0.05 vs. sham group; ## P < 0.05 vs. I/R group. S: sham-operated rats treated with saline; Q+S: sham-operated rats treated with quercetin; E+S: rats treated with rHuEPO; Q+E+S: sham-operated rats treated with quercetin and rHuEPO. B) The impact of quercetin on renal function. Note that there is significant increase in serum creatinine levels in the Q+E+I/R group compared with the E+I/R group. # P < 0.05 vs. sham group; ## P < 0.05 vs. I/R group; *P < 0.05 vs. E+I/R group. C, D) The influence of quercetin on tubular necrosis. Note that there is a significant increase in the necrosis score in the Q+E+I/R group compared with the E+I/R group. # P < 0.05 vs. sham group; ## P < 0.05 vs. I/R group; *P < 0.05 vs. E+I/R group. Q+I/R: rats pretreated with quercetin before I/R injury; Q+E+I/R: rats treated with quercetin and rHuEPO before I/R injury
